Published in Clin Cancer Res on September 01, 2008
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis (2012) 1.42
The SLC39 family of zinc transporters. Mol Aspects Med (2013) 1.41
Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol (2013) 1.11
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther (2012) 1.09
Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate (2012) 1.00
Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. Cancer Biol Ther (2011) 0.96
A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Mol Med (2013) 0.96
Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer (2014) 0.96
Reaction-based fluorescent sensor for investigating mobile Zn2+ in mitochondria of healthy versus cancerous prostate cells. Proc Natl Acad Sci U S A (2013) 0.94
Zinc and prostatic cancer. Curr Opin Clin Nutr Metab Care (2009) 0.94
Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis (2011) 0.84
Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: potential implication for prostate cancer therapy. Prostate (2011) 0.83
Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-kappaB-independent, proteasome-mediated mechanism. Mol Cancer (2010) 0.81
Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther (2015) 0.78
SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J (2016) 0.78
Zinc bells rang in Jerusalem! Sci Signal (2010) 0.77
LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. Br J Cancer (2017) 0.75
A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch Biochem Biophys (2016) 0.75
Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects. Bioinorg React Mech (2013) 0.75
The miR-183 family cluster alters zinc homeostasis in benign prostate cells, organoids and prostate cancer xenografts. Sci Rep (2017) 0.75
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem (1999) 2.76
Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene (2001) 2.71
The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer (2006) 2.70
Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene (2006) 2.60
The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology (2000) 2.36
The SLC39 family of metal ion transporters. Pflugers Arch (2003) 2.27
hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer (2005) 2.21
Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate (1998) 2.13
Functional expression of the human hZIP2 zinc transporter. J Biol Chem (2000) 2.07
Targeting XIAP for the treatment of malignancy. Cell Death Differ (2006) 2.04
Overview of mammalian zinc transporters. Cell Mol Life Sci (2004) 1.90
The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells. J Biol Chem (2001) 1.86
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate (2002) 1.86
Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem (1999) 1.86
Zinc in the human prostate gland: normal, hyperplastic and cancerous. Int Urol Nephrol (1997) 1.84
Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology (1998) 1.73
Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem (2003) 1.66
Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys (2007) 1.65
Regulation of the zinc transporter ZnT-1 by dietary zinc. Proc Natl Acad Sci U S A (1998) 1.60
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Zinc induces mitochondria apoptogenesis in prostate cells. Mol Urol (2000) 1.51
Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate (2002) 1.46
Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res (2004) 1.44
BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res (1998) 1.41
Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl Immunohistochem Mol Morphol (2003) 1.37
Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis (2006) 1.33
Characterization of the role of IL-6 in the progression of prostate cancer. Prostate (1999) 1.33
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res (2002) 1.28
Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell Int (2006) 1.26
Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer (2001) 1.24
Mitochondrial control of apoptosis: an overview. Biochem Soc Symp (1999) 1.23
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res (2005) 1.19
Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer (1989) 1.17
Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res (2001) 1.13
Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. Cancer Res (2001) 1.03
Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett (2004) 1.00
Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res (2007) 0.98
Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol (1999) 0.98
Androgen-mediated resistance to apoptosis. Prostate (2002) 0.97
The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma. J Surg Oncol (2008) 0.95
Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res (1995) 0.93
Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es). Cell Growth Differ (1997) 0.87
Serum-Zn-levels in prostatic cancer. Urol Res (1989) 0.81
Targeting the Bcl-2 family in cancer therapy. Semin Oncol (2006) 0.81
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol (2009) 6.71
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol (2006) 3.88
Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol (2011) 2.87
Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer (2008) 2.75
Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology (2011) 2.20
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol (2012) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer (2008) 1.64
Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol (2012) 1.64
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Enhancing renal masses with zero net growth during active surveillance. J Urol (2007) 1.59
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology (2012) 1.54
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49
Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol (2002) 1.48
Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int (2014) 1.47
Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology (2011) 1.46
Robot-assisted partial nephrectomy: a large single-institutional experience. Urology (2010) 1.45
Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Can J Urol (2012) 1.45
Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol (2010) 1.44
Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care (2015) 1.41
Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. J Urol (2012) 1.40
The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol (2017) 1.39
How Hugh Hampton Young's treatment of President Woodrow Wilson's urinary retention and urosepsis affected the resolution of World War I. J Urol (2011) 1.38
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer (2004) 1.38
Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol (2008) 1.37
Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) (2009) 1.36
Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis (2006) 1.33
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res (2002) 1.28
Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
Contemporary management of small renal masses. Eur Urol (2011) 1.19
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer (2007) 1.18
A review of contemporary data on surgically resected renal masses--benign or malignant? Urology (2013) 1.15
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res (2003) 1.13
Predicting growth of solid renal masses under active surveillance. Urol Oncol (2008) 1.11
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther (2012) 1.09
Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol (2003) 1.06
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2013) 1.06
Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw (2009) 1.05
Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol (2008) 1.05
Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol (2007) 1.05
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int (2009) 1.05
Incidence and management of penetrating renal trauma in patients with multiorgan injury: extended experience at an inner city trauma center. J Urol (2004) 1.04
Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol (2011) 1.02
Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer (2014) 1.02
Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.01
Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol (2012) 1.01
Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. J Urol (2012) 1.01
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate (2012) 1.00
Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate (2013) 0.99
Evaluation and management of the renal mass. Med Clin North Am (2011) 0.99
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer (2005) 0.97
Active surveillance: a potential strategy for select patients with small renal masses. Future Oncol (2011) 0.97
Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate (2007) 0.96
Renal masses herniating into the hilum: technical considerations of the "ball-valve phenomenon" during nephron-sparing surgery. Urology (2009) 0.96
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 0.96
Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol (2012) 0.96
Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One (2011) 0.95
Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. Can J Urol (2013) 0.95
Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene (2005) 0.95
Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene (2008) 0.95
Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU Int (2012) 0.94
Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol (2013) 0.94
The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer (2014) 0.94
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys (2005) 0.94
The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet (2004) 0.93